{"product_id":"sandoz-pestle-analysis","title":"Sandoz Group PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how regulatory shifts, market pricing pressures, and biotech innovation converge to shape Sandoz Group’s strategic path—our PESTLE snapshot highlights the external risks and opportunities driving future growth. Ideal for investors, strategists, and advisors, the full PESTLE delivers actionable insights and ready-to-use slides to inform decisions. Download the complete analysis now for a data-backed competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Pricing Interventions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational governments are imposing price controls and mandatory discounts to curb healthcare spending, with OECD countries reporting average medicine price reductions of 5–12% in 2023–2024; the US Inflation Reduction Act’s drug price negotiation framework, targeting high-cost biologics, pressures list prices and accelerates biosimilar uptake—projected to save Medicare $98 billion 2024–2033—forcing Sandoz to adapt reimbursement strategies to protect margins while advancing affordable access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Supply Chain Security\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical tensions between China, the US and EU have driven policies favoring domestic pharma manufacturing; 2024 EU and US subsidies for reshoring reached over €8.5bn and $6.2bn respectively to secure critical supply chains.\u003c\/p\u003e\n\u003cp\u003eGovernments in Europe and North America are incentivizing reshoring of API production—EU estimates aim to double local API capacity by 2027 to cut reliance on single-source regions from ~60% to under 35%.\u003c\/p\u003e\n\u003cp\u003eSandoz, with ~70% of its manufacturing in Europe, is well positioned to capture reshoring demand but faces margin pressure as Western production costs are typically 20–30% higher than Asian alternatives; careful cost management is required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform and Universal Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical moves toward universal healthcare in emerging markets are expanding the TAM for generics; WHO estimates 2 billion people gained improved access to essential medicines initiatives by 2024, boosting generics demand by ~6–8% CAGR in those regions. Legislative pushes to cut out-of-pocket costs increasingly favor biosimilars; biosimilar uptake grew 22% globally in 2023 as payers sought lower-cost biologic alternatives. Sandoz has secured multiple national tenders and state partnerships—supplying essential medicines in over 40 countries and capturing double-digit share in several public markets—positioning it as a preferred provider amid policy shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory cooperation between FDA and EMA, including ICH and pilot reliance pathways, is reducing duplicative trials for complex generics and biosimilars, cutting approval timelines—EMA reported reliance use rose ~25% in 2024—supporting Sandoz’s faster multi-jurisdiction launches and potential revenue gains from quicker market access.\u003c\/p\u003e\n\u003cp\u003eProtectionist policy shifts in some markets (tariff or local-data requirements) still cause regional delays, necessitating targeted government affairs; 2024 trade-restrictive measures increased 8% globally per WTO, raising compliance costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA–EMA harmonization up ~25% reliance use (2024)\u003c\/li\u003e\n\u003cli\u003eReduces duplicative trials, speeds time-to-market\u003c\/li\u003e\n\u003cli\u003eWTO: trade-restrictive measures +8% (2024)\u003c\/li\u003e\n\u003cli\u003eRequires targeted government affairs to mitigate local hurdles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade Policies and Tariff Barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChanges in international trade agreements and tariffs on chemical precursors can raise Sandoz’s COGS; for example, a 5-10% tariff on key APIs could add millions to annual costs given Sandoz’s 2024 revenues of about €8.0bn for Novartis’s Sandoz division.\u003c\/p\u003e\n\u003cp\u003eSandoz continuously monitors EU trade relations—notably EU-US and EU-India talks—to anticipate import duties and regulatory shifts that affect supply chains.\u003c\/p\u003e\n\u003cp\u003eStrategic sourcing and supplier diversification reduce exposure; in 2023 Sandoz expanded Asian and European supplier contracts to lower single‑supplier risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariff shock (5–10%) risks raising COGS\u003c\/li\u003e\n\u003cli\u003e2024 pro forma revenue context: ~€8.0bn\u003c\/li\u003e\n\u003cli\u003eActive monitoring of EU trade partners\u003c\/li\u003e\n\u003cli\u003eSupplier diversification to mitigate duty-driven disruptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz: Reshoring boosts biosimilar growth but squeezes margins amid rising Western costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrice controls and IRA-led US negotiations pressure margins while boosting biosimilar uptake (global biosimilar growth 22% in 2023); reshoring subsidies (€8.5bn EU, $6.2bn US in 2024) favor Sandoz’s Europe-heavy manufacturing (~70%) but raise costs (Western production +20–30%); API reshoring aims to cut single-source reliance from ~60% to \u0026lt;35% by 2027; FDA–EMA reliance ↑25% (2024) speeds launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 pro forma revenue (Sandoz)\u003c\/td\u003e\n\u003ctd\u003e~€8.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar growth (2023)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReshoring subsidies (2024)\u003c\/td\u003e\n\u003ctd\u003eEU €8.5bn; US $6.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWestern production cost premium\u003c\/td\u003e\n\u003ctd\u003e+20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA–EMA reliance change (2024)\u003c\/td\u003e\n\u003ctd\u003e+25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Sandoz across Political, Economic, Social, Technological, Environmental and Legal dimensions, with data-backed trends and forward-looking insights to identify risks and opportunities for executives, investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Sandoz that can be dropped into presentations or shared across teams to quickly align on external risks, regulatory shifts, and market drivers—editable for region- or business-line–specific notes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation in energy, labor, and raw material costs—energy prices up ~18% y\/y in 2024 and global generic API costs rising ~12%—squeezes the thin margins of the generic pharma sector where gross margins often sit in the mid-20s%. Sandoz leans on operational excellence and centralized procurement, citing €300m+ cost-savings targets in 2024–25 to offset input inflation. With many markets subject to fixed government pricing, ability to pass costs is constrained, leaving efficiency as the main margin lever.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Swiss-based firm, Sandoz faces FX risk from CHF\/EUR and CHF\/USD swings; a 10% CHF appreciation vs EUR in 2024 would compress reported Euro revenues materially given ~40% EU sales. The group used hedges covering roughly 60–70% of short-term exposure in 2024 and levers geographic revenue mix—45% North America, 40% Europe in 2024—to offset CHF strength and protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpeconomic expansion in southeast asia and latin america growth of respectively driving higher healthcare spending a annual rise generics demand benefiting sandoz product mix.\u003e\n\u003cpsandoz is prioritizing market entry and supply investments in these regions to diversify revenue from mature western markets where growth low single digits.\u003e\n\u003cpsuccess hinges on local economic stability and rising middle-class purchasing power latin america middle class grew to of the population in improving affordability for branded generics.\u003e\n\u003c\/psuccess\u003e\u003c\/psandoz\u003e\u003c\/peconomic\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe higher global interest rates—US Fed funds at 5.25–5.50% (2024) and ECB policy around 4.00%—raise Sandoz’s debt servicing costs and make funding new manufacturing sites more expensive, pressuring capex timing.\u003c\/p\u003e\n\u003cp\u003eSandoz’s disciplined capital allocation prioritizes sustainable biosimilar R\u0026amp;D, limiting net debt growth (Novartis Group net debt\/EBITDA target range maintained through 2024 guidance).\u003c\/p\u003e\n\u003cp\u003eElevated rates compress valuations for acquisition targets in generics, reducing deal activity and lowering expected purchase multiples versus 2021–22 levels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher rates increase capex borrowing costs and extend payback periods\u003c\/li\u003e\n\u003cli\u003eCapital allocation preserves R\u0026amp;D funding while constraining large one‑off investments\u003c\/li\u003e\n\u003cli\u003eAcquisition valuations down, reducing M\u0026amp;A volume and pricing expectations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost Containment in Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpeconomic pressures on national budgets push providers toward biosimilars global biosimilar savings estimated at over usd billion by bolster adoption benefiting sandoz as major biologics face patent cliffs.\u003e\n\u003cpsandoz emphasizes long-term value and system-wide savings studies show biosimilars can reduce biologic costs by secure formulary placement payer contracts.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal projected biosimilar savings \u0026gt; USD 100bn by 2028\u003c\/li\u003e\n\u003cli\u003eCost reductions per biologic 20–40%\u003c\/li\u003e\n\u003cli\u003ePayers favor biosimilars after major patent expiries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psandoz\u003e\u003c\/peconomic\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSandoz combats input inflation with €300M+ cuts, 65% FX hedge as biosimilars surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflationary input costs and fixed pricing squeeze mid-20s% gross margins; Sandoz targets €300m+ savings (2024–25) and hedged ~65% FX exposure in 2024 to protect ~45% NA\/40% EU revenue. Emerging markets grew ~4.5% (SE Asia) and 3.2% (LatAm) in 2024, boosting generics demand 6–8%. Fed\/ECB rates (2024) raised capex costs; biosimilars projected \u0026gt;USD100bn savings by 2028.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy inflation\u003c\/td\u003e\n\u003ctd\u003e+18% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric API costs\u003c\/td\u003e\n\u003ctd\u003e+12% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHedge coverage\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost savings target\u003c\/td\u003e\n\u003ctd\u003e€300m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar savings\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;USD100bn by 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSandoz Group PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Sandoz Group PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use without placeholders or edits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751857893753,"sku":"sandoz-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sandoz-pestle-analysis.png?v=1772235416","url":"https:\/\/growthsharematrix.com\/products\/sandoz-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}